Eton Pharmaceuticals, Inc. (ETON) AI Stock Analysis

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to advancing and commercializing pharmaceutical products primarily focused on addressing rare diseases. Its portfolio includes treatments such as Biorphen and Rezipres for anesthesia-related hypotension, Carglumic Acid for hyperammonemia from N-acetylglutamate Synthase deficiency, Alkindi Sprinkle for pediatric adrenocortical insufficiency, and EPRONTIA liquid topiramate. It also offers Alaway Preservative Free ophthalmic solution for allergic conjunctivitis. Eton's development pipeline includes Zonisamide Oral Suspension and Lamotrigine Oral Suspension for partial onset seizures, along with a cysteine injection, dehydrated alcohol injection, and a Zeneo hydrocortisone autoinjector.

Between FY2021 and FY2025, Eton's annual revenue expanded from $21.8M to $80.0M, representing a 5-year revenue CAGR of 359.6%. Annual gross margin contracted from 88.0% in FY2021 to 53.5% in FY2025, while operating margin improved from -6.8% to 0.1%. FY2025 net income stood at -$4.6M, though EPS registered at $0.07. Over the trailing twelve months, revenue reached $105.6M with an operating margin of 35.8% and net profit margin of 12.0%. For the latest quarter ended June 30, 2026, quarterly revenue grew 98.6% year-over-year, while quarterly earnings declined 12.6%.

As of June 30, 2026, Eton held $26.8M in cash and short-term investments against total debt of $29.0M, resulting in net debt of $2.1M. The company's current ratio stood at 1.52, and its debt-to-equity ratio was 0.62 on $46.6M in shareholders' equity. Operating cash flow improved to $10.5M in FY2025, supporting free cash flow of $10.2M after capital expenditures of $333,000. Over the past five years, the total share count increased by 26.3%.

ETON carries a market cap of $1.44B and an enterprise value of $1.59B. The stock trades at a trailing P/E of 125.8x and a forward P/E of 23.9x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 13.6x versus the peer median of 4.1x, and its EV/EBITDA is 76.4x versus 12.0x. Over the past year, ETON gained 174.3%, outperforming the S&P 500 (SPY) return of 16.8%. Its 5-year return is 865.6% compared to 83.0% for the S&P 500.

Wall Street coverage includes 4 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $71.50, representing a 42.1% upside compared to the last close of $50.31 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts anticipate revenue of $149.7M and EPS of $1.40. Eton has exceeded EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Eton Pharmaceuticals, Inc. (ETON). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ETON income statement, ETON balance sheet, ETON key metrics, ETON analyst forecast, ETON chart. See the ETON stock overview for the latest quote and news.